Other Pulmonary fibrosis drug developer Avalyn files IPO PharmaphorumAvalyn Pharma hops on the IPO train, filing to list on the Nasdaq and raise funds for late-stage trials of its inhaled pulmonary fibrosis therapies.OtherRespiratoryRead full story pharminent April 9, 2026 (Last updated: April 9, 2026) Pharmaphorum Avalyn Pharma hops on the IPO train, filing to list on the Nasdaq and raise funds for late-stage trials of its inhaled pulmonary fibrosis therapies. OtherRespiratoryRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Avalyn plots IPO to push inhaled pulmonary fibrosis pipeline through clinicNext: Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk Related Stories Other ASCO ’26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer pharminent June 2, 2026 Other ASCO26: Symptom-tracking app helps advanced cancer patients pharminent June 2, 2026 Other All eyes on Revolution, bispecific antibodies and more at ASCO26 pharminent May 26, 2026
